CompletedNot Applicable

Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

United States44 participantsStarted 2019-07-01

Plain-language summary

The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office Keravive by Hydrafacial treatments at Day 0 and Weeks 4 and 8 in combination with daily application on Keravive Peptide Spray at home. Subjects will be assessed at Day 0, and Weeks 4, 8, and 20 by investigators using the Norwood Scale (males), Ludwig Classification (females), and a series of Likert scales for ranking improvement in scalp health and hair quality.

Who can participate

Age range30 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Norwood Scale score of 2, 3 or 3 Vertex (males) and Ludwig Classification of Type I-1, I-2 or I-3 (females). Exclusion Criteria: * Non-study hair loss treatments (e.g., dutasteride, finasteride, minoxidil, nutraceuticals, PRP therapy, laser or LED scalp treatments, etc.) * Salon treatments such as straightening, perms or coloring.

What they're measuring

Hair Thinning and Temporal Hairline Recession

Timeframe: Day 0, Weeks 4, 8, and 20

Scalp Health

Timeframe: Weeks 4, 8, and 20

Hair Appearance

Timeframe: Day 0, Weeks 4, 8, and 20

Trial details

NCT IDNCT06112782

SponsorBeauty Health

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-01-31

View on ClinicalTrials.gov More Androgenic Alopecia trials